Poster Session A

Wednesday, January 16
4:30-7:00 p.m.

A01  Clinical detection of melanoma via endogenous fluorophore lifetime imaging. Peter Pellionisz. UCLA David Geffen School of Medicine, Los Angeles, CA.

A02, PR07  The role of keratinocyte desmoglein 1 in shaping the melanoma tumor niche. Hope Burks. Northwestern University, Feinberg School of Medicine, Chicago, IL.

A03, PR08  Identifying the molecular and environmental factors mediating transformation of melanocyte stem cells to melanoma. Andrew White. Cornell University, Ithaca, NY.

A04  Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. Fernando Cintra Lopes Carapeto. University of Texas MD Anderson Cancer Center, Houston, TX.

A05  Molecular, immunological, metabolic, and radiomic associations of oxidative phosphorylation (OXPHOS) in melanoma brain metastases (MBMs). Grant Fischer. The University of Texas MD Anderson Cancer Center, Houston, TX.

A06  Differential response to autophagy in primary versus melanoma cells. Isabelle Miousse. University of Arkansas for Medical Sciences, Little Rock, AR.

A07  Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition. Tyler Hitchman. MSKCC, New York, NY.

A08  The effect of irradiation with curcumin as a possible form of amelanotic melanoma treatment. Stanislaw Kwiatkowskis. Wroclaw Medical University, Wroclaw, Poland.

A09  Characteristics of uveal melanoma patients with central nervous system metastases. Sapna Patel. MD Anderson Cancer Center, Houston, TX.

A10, PR09  Pharmacological targeting of Gq reveals new pathways in uveal melanoma. Michael Onken. Washington University School of Medicine, Saint Louis, MO.

A11  Prognostic model for disease specific survival in anorectal melanoma. Priyadharsini Nagarajan. UT MD Anderson Cancer Center, Houston, TX.

A12  Presence of circulating tumor cells is an adverse risk factor for early stage uveal melanoma. Kartik Anand. Houston Methodist Cancer Center, Houston, TX.
A13 Clinical characteristics of responders to Nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma. Michael Shephard. UT MD Anderson Cancer Center, Houston, TX.

A14, PR13 PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Minjung Kim. University of South Florida, Tampa, FL.

A15 New treatment opportunities by in vivo and in vitro screening approaches in melanoma. Luisa Lanfrancone. European Institute of Oncology, Milan, Italy.

A16, PR14 Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma. Jaymes Farrell. Tufts University, Boston, MA.

A17 A versatile mouse-modeling platform for rapid in vivo melanoma studies. Florian Karreth. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

A18 Ccn1 expression by fibroblasts is required for melanoma metastasis. Andrew Leask. University of Western Ontario, London, ON, Canada.

A19 Discovery and characterization of selective and non-selective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. Lauren Lucas. Auburn University, Auburn, AL.

A20 17-aminogeldanamycin inhibits cytoprotective UPR pathways and cooperates with inhibitors of the MAPK signaling cascade in apoptosis induction. Aleksandra Mielczarek-Lewandowska. Medical University of Lodz, Lodz, Poland.

A21 Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene. David Riese. Auburn University, Auburn, AL.


A23 Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. Stephen Mok. MD Anderson Cancer Center, Houston, TX.

A24, PR02 Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype. Arthur Liu. The University of Texas MD Anderson Cancer Center, Houston, TX.

A25, PR01 A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Livnat Jerby-Arnon. The Broad Institute of MIT and Harvard, Cambridge, MA.

A26 Humanized mouse model: A model to understand mechanisms of immune non-responsiveness to immune checkpoint inhibitors in melanoma. Rajasekharan Somasundaram. The Wistar Institute, Philadelphia, PA.

A27 Engineering a 3D melanoma microenvironment and identifying novel therapeutic targets. Vasanth Siruvallur Murali. UT Southwestern Medical Center, Dallas, TX.
A28 Identification of NGLY1-mediated protein deglycosylation as a vulnerable point in melanoma. Yu-Chieh Wang. University of North Texas Health Science Center, Fort Worth, TX.


A30, PR03 Non-Genomic BAP1 Aberrancy Drives Highly Aggressive Cutaneous Melanoma Phenotype. Scott Woodman. University of Texas MD Anderson Cancer Center, Houston, TX.

A31 A novel melanoma derived cyclic decapeptide dimer mediates restoration of contact inhibition of growth and reversal of the malignant phenotype. George Lipkin. NYU Langone School of Medicine, New York, NY.

PR06 The glutaminase inhibitor CB-839 potentiates anti-melanoma activity of standard-of-care targeted therapies and immunotherapies. Vashisht Yennu Nanda. UT M.D. Anderson Cancer Center, Houston, TX.